https://orcid.org/0000-0002-3909-5698
References
- United States Food and Drug Administration. Available from: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed February 17, 2019.
- Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society Guidelines. Can J Cardiol. 2011;27:208–221. doi:10.1016/j.cjca.2010.12.033
- Mehta SR, Bainey KR, Cantor WJ, et al. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol. 2018;34:214–233. doi:10.1016/j.cjca.2017.12.012
- ClinicalTrials.Gov. Tailored antiplatelet therapy following PCI (TAILOR-PCI). Available from: https://clinicaltrials.gov/ct2/show/NCT01742117. Accessed February 17, 2019.
- ClinicalTrials.Gov. Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes (PHARMCLO). Available from: https://clinicaltrialsgov/ct2/show/NCT03347435?term=ardissino&rank=1. Accessed February 17, 2019.
- BioScience Spartan Rx CYP2C19. Available from: https://www.spartanbio.com/. Accessed February 17, 2019.
- Roberts JD, Wells GA, LeMay MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379:1705–1711. doi:10.1016/S0140-6736(12)60161-5
- Kamal RN, Lindsay SE, Eppler SL. Patients should define value in health care: a conceptual framework. J Hand Surg Am. 2018;S0363–5023(0317)31764–31761. doi:10.31016/j.jhsa.32018.31703.31036.
- Louviere J, Hensher D, Swait J. Stated Choice Methods. Cambridge: Cambridge University Press; 2000.
- EKOS Research. Available from: www.ekos.com. Accessed February 17, 2019.
- University of Ottawa. Available from: https://www.ottawaheart.ca/heart-condition/acute-coronary-syndrome. Accessed March 29, 2017.
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015. doi:10.1056/NEJMoa0706482
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. doi:10.1056/NEJMoa0904327
- Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362. doi:10.1056/NEJMoa0809171
- Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119:2553–2560. doi:10.1161/CIRCULATIONAHA.109.851949
- Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphism on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–1328. doi:10.1016/S0140-6736(10)61274-3
- Gafni A. Willingness to pay as a measure fo benefits. Relevant questions in the context of public decisionmaking about healthcare programs. Med Care. 1991;29:1246–1252. doi:10.1097/00005650-199112000-00007
- Microsoft Corporation. Microsoft excel. 2013.
- Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making. A user’s guide. Pharmacoeconomics. 2008;26:661–677. doi:10.2165/00019053-200826080-00004
- Rowen D, Stevens K, Labeit A, et al. Using a discrete-choice experiment involving cost to value a classification system measuring the quality-of-life impact of self-management for diabetes. Value Health. 2018;21:69–77. doi:10.1016/j.jval.2017.06.016
- Ratcliffe J. The use of conjoint analysis to elicit willingness-to-pay values: Proceed with caution? Int J Technol Assess Health Care. 2000;16:270–275. doi:10.1017/S0266462300161227